Head and neck cancer: improving outcomes with a multidisciplinary approach
C Lo Nigro, N Denaro, A Merlotti… - Cancer management and …, 2017 - Taylor & Francis
For early-stage head and neck cancer (HNC), surgery (S) or radiotherapy (RT) is a standard
treatment. The multidisciplinary approach, which includes multimodality treatment with S …
treatment. The multidisciplinary approach, which includes multimodality treatment with S …
Weekly low‐dose versus three‐weekly high‐dose cisplatin for concurrent chemoradiation in locoregionally advanced non‐nasopharyngeal head and neck cancer: a …
Background Three‐weekly high‐dose cisplatin (100 mg/m2) is considered the standard
systemic regimen given concurrently with postoperative or definitive radiotherapy in locally …
systemic regimen given concurrently with postoperative or definitive radiotherapy in locally …
Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy …
HS Antunes, D Herchenhorn, IA Small, CMM Araújo… - Oral oncology, 2017 - Elsevier
Background The impact of low-level laser therapy (LLLT) to prevent oral mucositis in
patients treated with exclusive chemoradiation therapy remains unknown. This study …
patients treated with exclusive chemoradiation therapy remains unknown. This study …
Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational …
A Schröck, A Leisse, L de Vos, H Gevensleben… - Clinical …, 2017 - academic.oup.com
BACKGROUND Circulating cell-free DNA methylation testing in blood has recently received
regulatory approval for screening of colorectal cancer. Its application in other clinical …
regulatory approval for screening of colorectal cancer. Its application in other clinical …
Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy
JM Caster, KY Stephanie, AN Patel, NJ Newman… - … , Biology and Medicine, 2017 - Elsevier
Nanoparticle (NP) chemotherapeutics can improve the therapeutic index of
chemoradiotherapy (CRT). However, the effect of NP physical properties, such particle size …
chemoradiotherapy (CRT). However, the effect of NP physical properties, such particle size …
[HTML][HTML] Immunotherapy in head and neck cancer: aiming at EXTREME precision
P Szturz, JB Vermorken - BMC medicine, 2017 - Springer
Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …
Long-term toxicities in 10-year survivors of radiation treatment for head and neck cancer
Objectives To characterize the recognized but poorly understood long-term toxicities of
radiation therapy (RT) for head and neck cancer (HNC). Materials and methods We …
radiation therapy (RT) for head and neck cancer (HNC). Materials and methods We …
The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma
Human papillomavirus positive oropharyngeal cancer (HPV-positive OPC) is a distinct
subtype of head and neck carcinoma (HNC) distinguished from HPV-negative HNC by its …
subtype of head and neck carcinoma (HNC) distinguished from HPV-negative HNC by its …
Immunotherapy of head and neck cancer: emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
Recent advances have permitted successful therapeutic targeting of the immune system in
head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets …
head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets …
[HTML][HTML] Primary concurrent chemoradiation in head and neck cancers with weekly cisplatin chemotherapy: analysis of compliance, toxicity and survival
Introduction Concurrent chemoradiation is the standard of care in inoperable locally
advanced squamous cell head and neck cancers. The most widely accepted schedule of …
advanced squamous cell head and neck cancers. The most widely accepted schedule of …